TOTUM-448

DIETARY_SUPPLEMENT2 trials

Sponsors

Valbiotis

Conditions

MASLDMild Inflammatory ContextNAFLDNon-Alcoholic Fatty Liver Disease

Unknown Phase

Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption

CompletedNCT06047847

ValbiotisMASLD, Mild Inflammatory Context, NAFLD

Start: 2023-09-27End: 2024-04-11Updated: 2024-05-31

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

RecruitingNCT06704321

ValbiotisNon-Alcoholic Fatty Liver Disease

Start: 2024-01-31End: 2025-12-31Target: 70Updated: 2024-11-26